NCT01727713View on ClinicalTrials.gov

Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

PHASE3CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2014

Conditions

Tourette's DisorderTic Disorder

Interventions

DRUG

Aripiprazole

Open Label: Once-Daily formulation of aripiprazole flex dose regimine

Trial Locations (33)

Unknown

Dothan

Goodyear

Orange

Sacramento

Wildomar

Norwich

Bradenton

Orange City

Tampa

Atlanta

Indianapolis

Waldorf

Bloomfield Hills

Mount Arlington

Summit

Manhasset

Rochester

Avon Lake

Cleveland

Houston

San Antonio

Orem

Salt Lake City

Norfolk

Petersburg

Bellevue

Toronto

Whitby

Nova Scotia

Budapest

Szeged

Catania

Milan

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01727713 - Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder | Biotech Hunter | Biotech Hunter